CLINICAL IMMUNOLOGY
Innate immunity gene expression changes in critically ill patients with sepsis and disease-related malnutrition
Submission date: 2015-06-26
Acceptance date: 2015-07-14
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):311-324
KEYWORDS
ABSTRACT
The aim of this study was an attempt to determine whether the expression of genes involved in innate antibacterial response (TLR2, NOD1, TRAF6, HMGB1 and Hsp70) in peripheral blood leukocytes in critically ill patients, may undergo significant changes depending on the severity of the infection and the degree of malnutrition. The study was performed in a group of 128 patients with infections treated in the intensive care and surgical ward. In 103/80.5% of patients, infections had a severe course (sepsis, severe sepsis, septic shock, mechanical ventilation of the lungs). Clinical monitoring included diagnosis of severe infection (according to the criteria of the ACCP/SCCM), assessment of severity of the patient condition and risk of death (APACHE II and SAPS II), nutritional assessment (NRS 2002 and SGA scales) and the observation of the early results of treatment. Gene expression at the mRNA level was analyzed by real-time PCR. The results of the present study indicate that in critically ill patients treated in the ICU there are significant disturbances in the expression of genes associated with innate antimicrobial immunity, which may have a significant impact on the clinical outcome. The expression of these genes varies depending on the severity of the patient condition, severity of infection and nutritional status. Expression disorders of genes belonging to innate antimicrobial immunity should be diagnosed as early as possible, monitored during the treatment and taken into account during early therapeutic treatment (including early nutrition to support the functions of immune cells).
REFERENCES (147)
1.
Angus DC, Linde-Zwirble WT, Lidicker J, et al. (2001): Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
2.
Husak L, Marcuzzi A, Herring J, et al. (2010): National Analysis of Sepsis Hospitalizations and Factors Contributing to Sepsis In-Hospital Mortality in Canada. Healthc Q 13 Spec No:35-41.13(Spec): 35-41.
3.
Gierek D, Kuczera M, Dąbek J, et al. (2011): Analiza leczenia chorych z ciężką sepsą w Oddziale Anestezjologii i Intensywnej Terapii Górnośląskiego Centrum Medycznego. Anestezjol Inten Terap 43: 22-28.
4.
Vincent JL, Sakr Y, Sprung CL, et al. (2006): Sepsis occurrence in acutely ill patients investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34: 344-353.
5.
Martin GS, Mannino DM, Eaton S, Moss M (2003): The epidemiology of sepsis in the United State from 1979 through 2000. N Engl J Med 348: 1546-1554.
6.
Riedemann NC, Guo RF, Ward PA (2003): The enigma of sepsis. J Clin Invest 112: 460-467.
7.
Mullard A (2011): Drug withdrawal sends critical care specialists back to basic. Lancet 378: 1760.
8.
McCulloh R, Opal SM (2013): Human recombinant lactoferrin for sepsis too good to be true? Crit Care Med 41: 908-909.
9.
Opal SM, Laterre PF, Francois B, et al. (2013): Effect of Eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis. The ACCESS randomized trial. JAMA 309: 1154-1162.
10.
Bone RC (1996): Immunologic dissonance: A continuing evolution in our understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS). Ann Intern Med 125: 680-687.
11.
Moore FA, Sauala A, Moore EE, et al. (1996): Postinjury Mulitple Organ Failure: A Bimodal Phenomenon. J Trauma 40: 501-512.
12.
Murphy TJ, Paterson HM, Mannick JA, Lederer JA (2004): Injury, sepsis, and regulation of Toll-like receptor responses. J Leukoc Biol 75: 400-407.
13.
Brochner AC, Toft P (2009): Pathophysiology of the systemic inflammatory response after major accidental trauma. Scand J Trauma Resusc Emerg Med 17: 43.
14.
Gentile LF, Cuenca AG, Philip A, et al. (2012): Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 72: 1491-1501.
15.
Hotchkiss RS, Monneret G, Payen D (2013): Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13: 862-874.
16.
Namath A, Patterson AJ (2009): Genetic polymorphisms in sepsis. Crit Care Clin 25: 835-856.
17.
Namath A, Patterson AJ (2011): Genetic polymorphisms in sepsis. Crit Care Nurs Clin North Am 23: 181-202.
18.
Dahmer MK, Randolph A, Vitali S, et al. (2005): Genetic polymorphisms in sepsis. Crit Care Med 6 (3 Suppl.): S61-S73.
19.
Wang H, Wei Y, Zeng Y (2014): The association of polymorphisms of TLR4 and CD14 genes with susceptibility to sepsis in a Chinese population. Medical Genetics 15: 123, 1-9.
20.
Arcaroli J, Fessler MB, Abraham E (2005): Genetic polymorphisms and sepsis. Shock. 24: 300-312.
21.
Markwart R, Condotta SA, Requardt RP, el al. (2014): Immunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell function. PLoS One 9: 1-13.
22.
McCall CE, Yoza BK, Liu T, Gazzar EI (2010): Gene-specific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun 2: 395-405.
23.
Kumpf O, Schumann RR (2010): Genetic variation in innate immunity pathways and their potential contribution to the SIRS/CARS debate – evidence from human studies and animal models. J Innate Immun 2: 381-394.
24.
Xiao W, Mindrinos MN, Seok J, et al. (2011): A genomic storm in critically injured humans. J Exp Med 208: 2581-2590.
25.
Wischmeyer PE (2011): Malnutrition in the acutely ill patient: is it more than just protein and energy? S Afr J Clin Nutr 24: 1-7.
26.
Hughes SM, Amadi B, Mwiya M, et al. (2009): Dendritic cell anergy results from endotoxemia in severe malnutrition. J Immunol 183: 2818-2826.
27.
Cabrera-Perez J, Condotta SA, Badovinac VP, et al. (2014): Impact of sepsis on CD4 T cell immunity. J Leukoc Biol 96: 767-777.
28.
Shubin NJ, Monaghan SF, Heffernan DS, et al. (2013): B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients. Critical Care 17: R276.
29.
Neelemaat F, Meijers J, Kruizenga H, et al. (2011): Comparison of five malnutrition screening tools in one hospital inpatient sample. J Clin Nurs 20: 2144-2152.
30.
Raslan M, Gonzalez MC, Dias MC, et al. (2011): Complementarity of Subjective Global Assessment (SGA) and Nutritional Risk Screening 2002 (NRS 2002) for predicting poor clinical outcomes in hospitalized patients. Clin Nutr 30: 49-53.
31.
Fowler RA, Adhikari NK, Bhagwanjee S (2008): Clinical review: critical care in the global context-disparities in burden of illness, access, and economics. Crit Care 12: 1-6.
32.
Nguyen YL, Angus DC, Boumendil A, Guidet B (2011): The challenge of admitting the very elderly to intensive care. Ann Intensive Care 1: 1-7.
33.
Baccaro F, Moreno JB, Borlenghi C, et al. (2007): Subjective global assessment in the clinical setting. JPEN J Parenter Enteral Nutr 31: 406-409.
34.
Singh H, Watt K, Veitch R, et al. (2006): Malnutrition is prevalent in hospitalized medical patients: are house staff identifying the malnourished patient? Nutrition 22: 350-354.
35.
Norman K, Pichard C, Lochs H, Pirlich M (2008): Prognostic impact of disease-related malnutrition. Clin Nutr 27: 5-15.
36.
Marik PE, Zaloga GP (2010): Immunonutrition in high-risk surgical patients. A systematic review and analysis of the literature. JPEN J Parenter Enteral Nutr 34: 378-386.
37.
Marik PE, Hooper M (2012): Immunonutrition in the critically ill. Immuno-Gastroenterology 1: 7-17.
38.
McClave SA, Martindale RG, Vanek VW, et al. (2009): Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) JPEN J Parenter Enteral Nutr 33: 277-316.
39.
Vidal-Casariego A, Calleja-Fernández A, Villar-Taibo R, et all. (2014): Efficacy of arginine-enriched enteral formulas in the reduction of surgical complications in head and neck cancer: a systematic review and meta-analysis. Clin Nutr 33: 951-957.
40.
Drover JW, Dhaliwal R, Weitzel L, et al. (2011): Perioperative use of arginine-supplemented diets: A systematic review of the evidence. J Am Coll Surg 212: 385-399.
41.
Mizock BA (2010): Immunonutrition and critical illness: an update. Nutrition 26: 701-707.
42.
Taylor B Joe Krenitsky J (2010): Nutrition in the Intensive Care Unit: Year in Review 2008–2009. JPEN J Parenter Enteral Nutr 34: 21-31.
43.
Hegazi RA, Paul E Wischmeyer PE (2011): Clinical review: optimizing enteral nutrition for critically ill patients – a simple data-driven formula. Crit Care 15: 234.
44.
Stechmiller JK, Childress B, Porter T (2004): Arginine immunonutrition in critically ill patients: A clinical dilemma. Am J Crit Care 13: 17-23.
45.
Zhou M, Martindale RG (2007): Arginine in the critical care setting. J Nutr 137 (6 Suppl 2): 1687S-1692S.
46.
Heyland DK, Dhaliwal R, Drover JW, et al. Canadian Critical Care Clinical Practice Guidelines Committee (2003): Canadian critical care clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 27: 355-373.
47.
Ortiz Leyba C, Montejo González JC, Vaquerizo Alonso C; Metabolism and Nutrition Working Group of the Spanish Society of Intensive Care Medicine andCoronary units (2011): Guidelines for specialized nutritional and metabolic support in the critically-ill patient: update. ConsensusSEMICYUC-SENPE: septic patient. Nutr Hosp 26 Suppl 2: 67-71.
48.
McClave SA, Martindale RG, Vanek VW, et al. American Society for Parenteral and Enteral Nutrition board of directors, American College of Critical Care Medicine, Society of Critical Care Medicine (2009):. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 33: 277-316.
49.
McClave SA, Hurt RT (2010): Clinical guidelines and nutrition therapy: better understanding and greater application to patient care. Crit Care Clin 26: 451-466.
50.
Wohlmuth C, Dünser MW, Wurzinger B, et al. (2010): Early fish oil supplementation and organ failure in patients with septic shock from abdominal infections: a propensity-matched cohort study. JPEN J Parenter Enteral Nutr 34: 431-437.
51.
Lenox CE, Bauer JE (2013): Potential adverse effects of omega-3 fatty acids in dogs and cats. J Vet Intern Med 27: 217-226.
52.
Calder PC, Jensen GL, Koletzko BV, et al. (2010): Lipid emulsions in Parenteral nutrition of intensive care patients: current thinking and future directions. Intensive Care Med 36: 735-749.
53.
Heyland D, Muscedere J, Wischmeyer PE, et al. (2013): Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 368: 1489-1497.
54.
García-de-Lorenzo A, Denia R, Atlan P, et al. (2005): Parenteral nutrition providing a restricted amount of linoleic acid in severely burned patients: a randomized double-blind study of an olive oil-based lipid emulsion v. medium/long-chain triacylglycerols. Br J Nutr 94: 221-230.
55.
Huschak G, Zur Nieden K, Hoell T, et al. (2005): Olive oil based nutrition in multiple trauma patients: a pilot study. Intensive Care Med 31: 1202-1208.
56.
Wanten GJA, Calder PC (2007): Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 85: 1171-1184.
57.
Singer P, Berger MM, Van den Berghe G, et al. (2009): ESPEN Guidelines on Parenteral Nutrition: Intensive care. Clin Nutr 28: 387-400.
58.
Granja C, Póvoa P, Lobo C, et al. (2013): The predisposition, infection, response and organ failure (Piro) sepsis classification system: results of hospitalmortality using a novel concept and methodological approach. PLoS ONE 8: e53885.
59.
de Groot B, Lameijer J, de Deckere ERJT, et al. (2014): The prognostic performance of the predisposition, infection, response and organ failure (PIRO) classification in high-risk and low-risk emergency department sepsis populations: comparison with clinical judgement and sepsis category. Emerg Med J 31: 292-300.
60.
Howell MD, Talmor D, Schuetz P, et al. (2011): Proof of principle: The predisposition, infection, response, organ failure sepsis staging system. Crit Care Med 39: 322-327.
61.
Desai KH, Tan ChS, Lekk JT, et al. (2011): Dissecting inflammatory complications in critically injured patients by within-patient gene expression changes: A longitudinal clinical genomic study. PLoS Med 8: e1001093.
62.
Wong HR (2012): Clinical review: Sepsis and septic shock-the potential of gene arrays Critical Care 16: 204-212.
63.
Cuenca AG, Gentile LF, Lopez MC, et al. (2013): Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med 41: 1-20.
64.
Talwar S, Munson PJ, Barrb J, et al. (2006): Gene expression profiles of peripheral blood leukocytes after endotoxin challenge in humans. Physiol Genomics 25: 203-215.
65.
Castellheim A, Brekke OL, Espevik T, et al. (2009): Innate immune responses to danger signals in systemic inflammatory syndrome and sepsis. Scandinavian Journal of Immunology 69: 479-491.
66.
Zhang QM, Raoof Y, Chen Y, et al. (2010): Circulating mitochondrial DAMPs cause inflammatory response to injury. Nature 464: 104-107.
67.
Punnet P, Yap CT, Wong Y, et al. (2010): SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328: 1290-1294.
68.
Fock RA, Vinolo MAR, Sá Rocha VM, et al. (2007) Protein-energy malnutrition decreases the expression of TLR-4/MD-2 and CD14 receptors in peritoneal macrophages and reduces the synthesis of TNF- in response to lipopolysaccharide (LPS) in mice. Cytokine 40: 105-114.
69.
Wischmeyer PE (2007): Glutamine: mode of action in critical illness. Crit Care Med 35 (9 suppl): S541-544.
70.
Garrel D, Patenaude J, Nedelec B, et al. (2003): Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med 31: 2444-2449.
71.
Kreymann KG, Berger MM, Neutz NE, et al. (2006): ESPEN guidelines on enteral nutrition: Intensive care. Clin Nutr 25: 210-223.
72.
Dutertius YM, Meguid MM, Pichard C (2009): Advancing from immunonutrition to pharmaconutrition:a gigantic challenge. Curr Opin Clin Nutr Metab Care 12: 398-403.
73.
Kessel A, Toubi E, Pavlotzky E, et al. (2008): Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat. Clin Exp Immunol 151: 341-347.
74.
Newsholme P (2001): Why is L-Glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr 131 (9 Suppl): 2515S-2522S.
75.
Singleton K, Beckey D, Virginia E, et al. (2005): Glutamine prevents activation of NF-B and stress kinase pathways, attenuates inflammatory cytokine release, and prevents acute respiratory distress syndrome (ARDS) following sepsis. Shock 24: 583-589.
76.
Berger MM, Chioléro RL (2007): Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med 35 (9 Suppl): S584-S590.
77.
Sukhotnik I, Agam M, Shamir R, et al. (2007): Oral glutamine prevents gut mucosal injury and improves mucosal recovery following lipopolysaccharide endotoxemia in a rat. J Surg Res 143: 379-384.
78.
Sukhotnik I, Mogilner J, Krausz MM, et al. (2004): Oral arginine reduces gut mucosal injury caused by lipopolysaccharide endotoxemia in rat. J Surg Res 122: 256-262.
79.
Sukhotnik I, Pollak Y, Coran AG (2014): Glutamine attenuates the inhibitory effect of methotrexate on TLR signaling during intestinal chemotherapy-induced mucositis in a rat. Nutr Metab (Lond) 11: 17.
80.
Taniguchi Y, Yoshioka N, Nakata K, et al. (2009): Mechanism for maintaining homeostasis in the immune system of the intestine. Anticancer Res 29: 4855-4860.
81.
Kędziora S , Słotwinski R, Dąbrowska A, et al. (2012): Glutamine abolishes the TLR-4 gene expression levels in pancreatic cancer patients: a preliminary study. Centr Eur.
83.
Słotwiński R, Dąbrowska A, Lech G, et al. (2014): Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progression. Cent Eur J Immunol 39: 498-507.
84.
Kondrup J, Rasmussen HH, Hamberg O, Stanga Z (2003): ESPEN working group. Nutritional risk screening (NRS 2002): new method based on an analysis of controlled clinical trials. Clinical Nutrition 22: 321-336.
85.
Baker JP, Detsky AS, Wesson DE, et al. (1982): Nutritional assessment: a comparison of clinical judgwmant and objective measures. N Engl J Med 306: 969-972.
86.
Bone RC, Balk RA; Cerra FB, et al. (1992): Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American Collage of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
87.
Levy MM, Fink MP, Marshall JC, et al. (2003): 2001 SCCM/ESICM/ACCP/ ATS/SIS international sepsis definitions conference. Crit Care Med 31: 1250-1256.
88.
Dellinger RP , Levy MM, Rhodes A, et al. (2013): Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med 39: 165-228.
89.
Livak KJ, Schmittgen TD (2001): Analysis of relative gene expression data using real-time quantitative PCR and 2(-Delta Delta C (T)) method. Methods 25: 402-408.
90.
Słotwiński R, Olszewski WL, Słodkowski M, et al. (2007): Can the interleukin-1 receptor antagonist (IL-1ra) be a marker of anti-inflammatory response to enteral immunonutrition in malnourished patients after pancreaticoduodenectomy? JOP 8: 759-769.
91.
Calvano SE, Xiao W, Richards DR, et al. (2005): A network-based analysis of systemic inflammation in humans. Nature 437: 1032-1037.
92.
Foteinou PT, Calvano SE, Lowry SF, Androulakis IP (2009):Modeling endotoxin-induced systemic inflammation using an indirect response approach. Math Biosci 217: 27-42.
93.
Digiandomenico A, Veach R A, Zienkiewicz J, et al. (2014) : The ‘‘Genomic Storm’’ induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation. PLoS ONE 9: e110183.
94.
Hawiger J, Musser JM (2011): How to approach genome wars in sepsis? Crit Care 15: 1007.
95.
Wong H R (2013): Genome-wide expression profiling in pediatric septic shock. Pediatric Research 73: 564-599.
96.
Cuenca AG, Gentile LF, Lopez MC, et al. (2013): Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med 41: 1175-1185.
97.
Słotwiński R, Słotwińska S, Kędziora S, et al. (2011): Innate immunity signaling pathways: links between immunonutrition and responses to sepsis. Arch Immunol Ther Exp 59: 79-87.
98.
Tsujimoto H, Ono S, Efron PA, et al. (2008): Role of Toll-like receptors in the development of sepsis. Shock 29: 315-321.
99.
Adib-Conquy M, Cavaillon JM (2007): Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Letters 581: 3723-3733.
100.
Sabroe I, Read RC, Whyte MKB, et al. (2003): Complex questions remain toll-like receptors in health and disease. J Immunol 171: 1630-1635.
101.
Armstrong L, Medford ALR, Hunter KJ, et al. (2004): Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 136: 312-319.
102.
Härter L, Mica L, Stocker R, et al. (2004): Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock 22: 403-409.
103.
Skinner NA, MacIsaac CM, Hamilton JA, Visvanathan K (2005): Regulation of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens. Clin Exp Immunol 141: 270-278.
104.
Williams, DL, Ha T, Li C, et al. (2003): Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 31: 1808-1818.
105.
Johnson SB, Matthew Lissauer M, Bochicchio GV, et al. (2007): Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 245: 611-621.
106.
Fahy RJ, Exline MR, Gavrilin MA, et al. (2008): Inflammasome mRNA expression in human monocytes during early septic shock. Am J Respir Crit Care Med 177: 983-988.
107.
Kanneganti T-D, Lamkanfi M, Nunez G (2007): Intracellular NOD-like receptors in host defense and disease. Immunity 27: 549-559.
108.
Clarke TB, Davis KM, Lysenko ES, et al. (2010): Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 16: 228-231.
109.
Delogu G, Lo Bosco L, Marandola M, et al. (1997): Heat shock protein (HSP70) expression in septic patients. J Crit Care 12: 188-192.
110.
Singleton KD, Wischmeyer PE (2006): Effects of HSP70.1/3 gene knockout on acute respiratory distress syndrome and the inflammatory response following sepsis. Am J Physiol Lung Cell Mol Physiol 290: L956-L961.
111.
Weiss YG, Bromberg Z, Raj N, et al. (2007): Enhanced heat shock protein 70 expression alters proteasomal degradation of IB kinase in experimental acute respiratory distress syndrome. Crit Care Med 35: 2128-2138.
112.
Hashiguchi N, Ogura H, Tanaka H, et al. (2001): Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. J Trauma 51: 1104-1109.
113.
Gelain DP, de Bittencourt Pasquali MA, Comim CM, et al. (2011): Serum heat shock protein 70 levels, oxidant status, and mortality in sepsis. Shock 35: 466-470.
114.
Schaaf B, Luitjens K Goldmann T, et al. (2009): Mortality in human sepsis is associated with downregulation of Toll-like receptor 2 and CD14 expression on blood monocytes. Diagn Pathol 4: 12.
115.
Tsujimoto H, Ono S, Majima T, et al. (2005): Neutrophil elastaze, MIP-2 and TLR-4 expression Turing human and experimental sepsis. Shock 23: 39-44.
116.
Tsujimoto H, Ono S, Majima, et al. (2006): Differential Toll-like receptor expression after ex vivo lipopolysaccharide exposure in patients with sepsis and following surgical stress. Clin Immunol 119: 180-187.
117.
Askanazi J, Carpentier YA, Michelsen CB, et al. (1980): Muscle and plasma amino acids following injury: influence of intercurrent infection. Ann Surg 192: 78-85.
118.
Oudemans-van Straaten HM, Bosman RJ, Treskes M, et al. (2001): Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med 27: 84-90.
119.
Yeh S-L, Lai Y-N, Shang H-F, et al. (2004): Effects of glutamine supplementation on innate immune response in rats with gut-derived sepsis. Br J Nutr 2004; 91: 423-429..
120.
Pérez-Bárcena J, Regueiro V, Marsé P, et al. (2008): Glutamine as a modulator of the immune system of critical care patients: effect on Toll-like receptor expression. A preliminary study. Nutrition 4: 522-527.
121.
Pérez-Bárcena J, Crespí C, Regueiro V, et al. (2010): Lack of effect of glutamine administration to boost the innate immune system response in trauma patients in the intensive care unit. Crit Care 14: R233.
122.
Chen QH, Yang Y, He HL, et al. (2014): The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials. Crit Care 18: R8.
123.
Yu M, Wang H, Ding A (2006): HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 174-179.
124.
Park JS, Svetkauskaite D, He Q, et al. (2004): Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377.
125.
Park JS, Gamboni-Robertson F, He Q (2006): High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924.
126.
Hreggvidsdóttir HS, Lundberg AM, Aveberger AC (2012): High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med 27: 224-230.
127.
Kang R, Chen R, Zhang Q, et al. (2014): HMGB1 in health and disease. Mol Aspects Med 40: 1-116.
128.
Bustin M (1999): Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal protein. Mol Cell Biol 19: 5237-5246.
129.
Wang H, Yang H, Czura, et al. (2001): HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164: 1768-1773.
130.
El Gazzar M (2007): HMGB1 modulates inflammatory responses in LPS-activated macrophages. Inflamm Res 56: 162-167.
131.
Schierrbeck H, Wahamaa H, Andersson U, et al. (2010): Immunomodulatoty drugs regulate HMGB1 release from activated human monocytes. Mol Med 16: 343-351.
132.
Cohen MJ, Brohi K, Calfee SC, et al. (2009): Early release of high mobility group box nuclear protein 1 after severe trauma in humans; role of injury severity and tissue hypoperfusion. Crit Care 13: R174.
133.
Tseng CC, Fang WF, Leung SY, et al. (2014): Impact of serum biomarkers and clinical factors on Intensive Care Unit mortality and 6-month outcome in relatively healthy patients with severe pneumonia and Acute Respiratory Distress Syndrome. Dis Markers 2014: 804654.
134.
Blander JM, Medzhitov R (2004): Regulation of phagosome maturation by signals from Toll-like receptors. Science 304: 1014-1018.
135.
Chen H, Wu Y, Zhang Y, et al. (2006): Hsp70 inhibits lipopolysaccharide-induced NF-B activation by interacting with TRAF6 and inhibiting its ubiquitination. FEBS Letters 580: 3145-3152.
136.
Sońdka Z, Tretyn A, Szeliga J, et al. (2006): Involvement of leucine Roch repeats (LRR) domain containing proteins in molecular mechanisms of inna te immunity of plants and Animals. Post Biol Kom 33: 635-656.
137.
Chamaillard M, Hashimoto M, Horie E, et al. (2003): An essential role for Nod1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4: 702-707.
138.
Girardin SE, Boneca IG, Viala J, et al. (2003): Nod2 is a general sensor of peptidoglycan through muramyl dipeptive (MDP) detection. J Biol Chem 278: 8869-8872.
139.
Lee JY, Hwang DH (2006): The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Mol Cells 21: 174-185.
140.
Jiang W, Wang X, Zeng B, et al. (2013): Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med 210: 2465-2476.
141.
Elke G, Wang M, Weiler N, et al. (2014): Close to recommended caloric and protein intake by enteral nutrition is associated with better clinical outcome of critically ill septic patients: secondary analysis of a large international nutrition database. Crit Care 18: R29.
142.
Ville S, Chiolero RL, Bollmann MD, et al. (2005): Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. Clinical Nutrition 24: 502-509.
143.
Marik PE, Zaloga GP (2008): Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 34: 1980-1990.
144.
Meng G, Grabiec A, Rutz M, et al. (2005): Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies. Immunol Lett 98: 200-207.
145.
Roger T, Calandra T (2009): TLR2-mediated neutrophil depletion exacerbates bacterial sepsis. PNAS 106: 6889-6890.
146.
Huang L, Yao Y, Sheng Z (2012): Novel insights for high mobility group box 1 protein-mediated cellular immune response in sepsis: A systemic review. World J Emerg Med 3: 165-171.
147.
Kim TH, Yoon SJ, Lee SM (2012): Genipin attenuates sepsis by inhibiting Toll-like receptor signaling. Mol Med 18: 455-465.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
